A new drug, ANX007, could be the first to protect vision in people with dry age-related macular degeneration (AMD). In the Phase 2 ARCHER study, monthly injections of ANX007 cut the risk of significant vision loss by 72% and preserved key retinal structures essential for vision. The developer of the drug, Annexon, plans on sharing…